Quality of life and effectiveness of vutrisiran as treatment for hereditary transthyretin amyloidosis
Farmacia Hospitalaria · 2026
DOI: 10.1016/j.farma.2025.12.010 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Farmacia Hospitalaria, 2026. Verfasst von Javier Corazón Villanueva und 1 weiteren Autor:innen. Beteiligte Einrichtung: Pharmacy Department, Hospital Clínico San Carlos, Madrid, Spain. Electronic address: javier.corazon@salud.madrid.org. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Quality of Life, Oligonucleotides. Die Arbeit nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
OBJECTIVES: To assess changes in quality of life in patients with rare disease hereditary transthyretin amyloidosis after initiating vutrisiran. Secondary objectives included evaluating effectiveness and safety. METHODS: Prospective, observational study, conducted in a real-world clinical setting between November 2023 and May 2024. Quality of life was assessed using Norfolk QOL-DN questionnaire at baseline and six months after treatment initiation. Statistical analysis was performed using SPSS Statistics®, and the Wilcoxon signed-rank test was applied to compare outcomes. RESULTS: Twenty-five patients were included. The median Norfolk QOL-DN score changed from 54 [40.5; 77.5] to 48 [32.0; 83.0] after six months (p = 0.935). NIS scores decreased from 41 [14.0; 70] to 22 [6.0; 66.5] (p = 0.177). Serum TTR levels were maintained or reduced to undetectable levels in all patients. NT-proBNP decreased from 464.0 [102.0; 827.0] to 345.0 pg/mL [146.0; 995.0] (p = 0.518). No treatment-related adverse events were reported. CONCLUSION: Although statistical significance was not reached, vutrisiran maintained or improved quality of life and clinical status in a real-world population that was more pretreated and had greater disease burden than the clinical trial. Combined with its favorable safety profile, subcutaneous administration, and extended dosing interval-preferred by patients-vutrisiran represents a promising therapeutic option for ATTRv amyloidosis. Long-term real-world studies are warranted to confirm these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pharmacy Department, Hospital Clínico San Carlos, Madrid, Spain. Electronic address: javier.corazon@salud.madrid.org.
- Pharmacy Department, Hospital Clínico San Carlos, Madrid, Spain.
Zitieren
APA
Corazón Villanueva, J., & García Sacristán, A. A. (2026). Quality of life and effectiveness of vutrisiran as treatment for hereditary transthyretin amyloidosis. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2025.12.010
Vancouver
Corazón Villanueva J, García Sacristán AA. Quality of life and effectiveness of vutrisiran as treatment for hereditary transthyretin amyloidosis. Farmacia Hospitalaria. 2026. doi:10.1016/j.farma.2025.12.010
BibTeX
@article{CoraznVillanueva2026,
author = {Corazón Villanueva, Javier and García Sacristán, Ana Andrea},
title = {Quality of life and effectiveness of vutrisiran as treatment for hereditary transthyretin amyloidosis},
journal = {Farmacia Hospitalaria},
year = {2026},
doi = {10.1016/j.farma.2025.12.010}
}
EUVIMED